{"id":"silodosin-capsules-control-group","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Dizziness"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"2-5%","effect":"Orthostatic hypotension"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Silodosin works by blocking alpha-1 adrenergic receptors in the smooth muscle of the prostate and bladder neck, leading to relaxation of these muscles and a decrease in the symptoms of benign prostatic hyperplasia (BPH). This results in improved urine flow and reduced symptoms of BPH.","oneSentence":"Silodosin is an alpha-1 adrenergic receptor antagonist.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:34:42.216Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Benign prostatic hyperplasia (BPH)"}]},"trialDetails":[{"nctId":"NCT07146386","phase":"PHASE3","title":"A Phase III Clinical Study of H077 Sustained-Release Tablets Compared With Silodosin Capsules in the Treatment of Benign Prostatic Hyperplasia","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Huilun Pharmaceutical Co., Ltd.","startDate":"2025-08","conditions":"Benign Prostatic Hyperplasia, Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms","enrollment":728},{"nctId":"NCT07068087","phase":"NA","title":"Silodosin in Facilitating Flexible Uretroscopy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ain Shams University","startDate":"2025-02-01","conditions":"Stone Ureter, Stone, Kidney","enrollment":42},{"nctId":"NCT00740779","phase":"PHASE2","title":"Use of Silodosin to Treat Moderate to Severe Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome.","status":"COMPLETED","sponsor":"Watson Pharmaceuticals","startDate":"2008-09","conditions":"Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome","enrollment":153}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Silodosin capsules Control Group","genericName":"Silodosin capsules Control Group","companyName":"Shanghai Huilun Pharmaceutical Co., Ltd.","companyId":"shanghai-huilun-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Silodosin capsules are used as a control group in a clinical study for the treatment of Benign Prostatic Hyperplasia. The study compares Silodosin capsules to H077 sustained-release tablets in the treatment of Benign Prostatic Hyperplasia.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}